Skip to content

Supine Exercise in Hepatopulmonary Syndrome Patients With Orthodeoxia

Design and Rationale for a Randomized Controlled Crossover Trial of Supine Versus Upright Exercise in Patients With Hepatopulmonary Syndrome and Orthodeoxia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04004104
Enrollment
10
Registered
2019-07-01
Start date
2019-07-24
Completion date
2024-08-31
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatopulmonary Syndrome

Keywords

Supine Exercise, Orthodeoxia

Brief summary

Hepatopulmonary syndrome (HPS) is a rare condition that presents in about a quarter of patients with liver cirrhosis. In addition, a small subset of these HPS patients also have orthodeoxia, defined as a drop in oxygen levels when they are sitting up (upright), as opposed to lying flat (supine). At present, there is little known about this condition. Patients diagnosed with HPS and orthodeoxia experience reduced ability to exercise, especially when upright. While standard cardiopulmonary exercise is routinely performed in the sitting position, there are machines that enable candidates to exercise in the supine position. This is especially relevant in patients with severe HPS, with clinically significant orthodeoxia, where conventional upright exercise is difficult. Currently there is a gap in the literature regarding the efficacy of supine exercise compared to upright exercise in these patients. Due to their improvement in dyspnea when lying supine, it is predicted that these patients will be able to exercise for a greater length of time and have increased exercise capacity, which can be projected to improve outcomes pre- and post-transplant. Overall, HPS patients tend to experience hypoxemia and exercise limitation. Exercise limitation impacts quality of life, incidence and severity of comorbid conditions, and in those who are liver transplant candidates, low exercise tolerance deleteriously impacts transplant outcomes. Accordingly, a strategy that enables patients to exercise more often and/or for longer periods would offer direct benefits to patients with HPS, and if employed as part of an exercise program, could also improve exercise capacity, and thus, liver transplant outcomes. The purpose of this study is to investigate the effect of supine, compared to upright position on exercise in patients with HPS and orthodeoxia. We hypothesize that these patients will be able to exercise for longer in the supine compared to the upright position, given improved oxygen levels when supine.

Detailed description

This is a 1 year randomized crossover controlled trial study of the effect of supine exercise position (intervention arm) compared to the upright exercise position (control arm) within 4 weeks. This is a single-center study conducted at St. Michael's Hospital, Toronto, Ontario. The exercise will be performed at a constant work rate, individualized for each participant. Peak work rate will be calculated using results from the most recent room air 6-minute walk test (6MWT), within the past 6 months. The equation used to estimate peak work rate is: Peak Work Rate = 0.168 x 6MWD (m) - 4.085 (ref Kozu Respirology 2010). The individualized constant work rate will be set at 70-80% of this estimated peak work rate. The main stopping criterion will be the point at which, after standardized encouragement, the subject is unable to continue because of symptoms (i.e. patient does not wish to continue or cannot maintain a minimum peddling frequency of 40 rpm for ≥ 10 seconds). This is defined as the tolerable limit (tLIM). Additional safety-related stopping criteria will include: the appearance of life-threatening arrhythmias, a drop in systolic blood pressure by ≥ 10 mm Hg from baseline, or a desaturation below a set point for ≥ 30 s. The set saturation point will be chosen individually for each patient, as the lower of: 80% or the lowest saturation seen on room air 6MWT. Exercise tests in each position, for each subject, will be standardized with respect to the proper seat adjustment relative to leg length and pedaling cadence (50-60 rpm). Inspiratory capacity will be measured before and after the exercise maneuver. The cycle ergometer resistance will be set to the pre-determined constant work rate, as described above. There will be continuous monitoring of saturation, ECG, gas exchange, blood pressure, and subjective dyspnea/leg fatigue (Borg scale), with standardized verbal encouragement throughout. Participants will be asked to bring running shoes and comfortable exercise clothes, ensure that they have eaten before the test, to take all usual medications, and to avoid major exercise for 24 hours before the test.

Interventions

DIAGNOSTIC_TESTUpright Exercise

Exercise is generally performed in the upright position.

DIAGNOSTIC_TESTSupine Exercise

Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

The assessor (different from the PI) will not be present when the two exercise tests are performed. Additionally, the results will not be labeled with the specific position of the exercise test. In this manner, the assessor will be blinded to the exercise position and this blinding will strengthen the validity of the research outcomes.

Intervention model description

Participants will be randomized (through a random-number generator, and with cancelled allocation) to start with either an upright exercise test (control arm) or a supine exercise test (intervention arm) on a bicycle ergometer, and then complete the alternate test within 4 weeks.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of moderate HPS (defined by liver disease, hypoxemia \[PaO2 \< 80 mmHg and AaDo2 (alveolar-arterial PO2 difference) ≥ 15 mmHg or ≥ 20 mmHg if age \> 64 years\] and IPVD (intrapulmonary vasodilatations) as shown by contrast echocardiography\]) 2. Presence of orthodeoxia (PaO2 decrease by \>4 mmHg when patient moves from supine to upright position).

Exclusion criteria

1. Pulmonary hypertension (echocardiographic estimated right ventricular systolic pressure \>/=50 mmHg and/or right heart catheterization mean pulmonary artery pressure \>25 mmHg with pulmonary capillary wedge pressure \</= 15 mmHg); 2. Significant obstructive ventilatory impairment (FEV1/FVC ratio \< 0.65) (FEV=forced expiratory volume in 1 second; FVC=forced vital capacity) 3. Known significant coronary artery disease; 4. Significant neurologic, orthopedic or rheumatological disorders preventing the use of a cycle ergometer; 5. Other absolute contraindications to submaximal tests (uncontrolled cardiac arrhythmia with hemodynamic compromise, symptomatic severe aortic stenosis, decompensated heart failure and acute cardiopulmonary illness); 6. Moderate or severe ascites.

Design outcomes

Primary

MeasureTime frameDescription
Stopping time (tLIM)12 monthsThe main stopping criterion will be the point at which, after standardized encouragement, the subject is unable to continue because of symptoms \[defined as the tolerable limit (tLIM)\]. Additional safety-related stopping criteria will include: the appearance of complex ventricular arrhythmias, intraventricular and/or atrioventricular conduction disorders, bradyarrhythmias, or a desaturation below a set point for ≥ 10 s. The set saturation point will be chosen individually for each patient, as the lower of: 80%, or the nadir desaturation seen on room air six-minute walk test (6MWT).

Secondary

MeasureTime frameDescription
Isotime Oxygen Uptake (VO2)12 monthsComparing oxygen uptake in the supine and upright position.
Dyspnea12 monthsPatient's subjective measure of shortness of breath using Borg scale. This scale ranges from 0 to 10, with 0 being no shortness of breath to 10 being maximal shortness of breath.
Leg Fatigue12 monthsPatient's subjective measure of leg fatigue using Borg scale. This scale ranges from 0 to 10, with 0 being no leg fatigue at all to 10 being maximal leg fatigue.
Arterial Oxygen Saturation12 monthsThe saturation of oxygen in the arteries.
Change in Inspiratory Capacity12 monthsMeasuring volume of air that can be maximally inspired after normal tidal breaths and comparing between supine and upright.
Reason for Stopping Exercise12 monthsReason due to which tLIM was reached and exercise was stopped.
Minute Ventilation (VE)12 monthsThe quantity of air expired out of the lungs per minute.
Heart Rate12 monthsThe number of heart beats per minute, also known as pulse.
VCO212 monthsCarbon dioxide output per unit of time.
Work Rate12 monthsConstant work rate / resistance at which the cycle ergometer was set.
HR over VO212 monthsThe change of heart rate to the volume of oxygen consumed in respiration over a period of time.
VE over time12 monthsThe change of VE during the entire duration of the exercise.
VO2/ HR over time12 monthsThe change of oxygen pulse during the entire duration of the exercise.
Heart rate over time12 monthsThe change of heart rate during the entire duration of the exercise.
Cardiac output12 monthsThe volume of the blood pumped by the heart through the circulatory system in a minute.
Change in inspiratory capacity12 monthsThe difference of the maximum volume of air that can be inspired following a normal, quiet expiration
VE max12 monthsMaximum minute ventilation
End tidal CO2 over time12 monthsThe point at the end of exhalation when the CO2 reaches its highest concentration.
VCO2 over VO212 monthsThe volume of carbon dioxide produced to the volume of oxygen consumed in respiration over a period of time, also known as respiratory quotient (RQ).

Countries

Canada

Contacts

Primary ContactSamir Gupta, MD, MSc
GuptaS@smh.ca(416) 864-6060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026